Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 82.22M P/E - EPS this Y 10.80% Ern Qtrly Grth -
Income -44.8M Forward P/E -1.35 EPS next Y -140.90% 50D Avg Chg -10.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -11.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -44.00%
Recommedations 2.00 Quick Ratio 1.64 Shares Outstanding 61.90M 52W Low Chg 35.00%
Insider Own 31.12% ROA -96.17% Shares Float 42.69M Beta 0.88
Inst Own 11.69% ROE - Shares Shorted/Prior 2.25M/2.10M Price 1.38
Gross Margin - Profit Margin - Avg. Volume 60,974 Target Price -
Oper. Margin - Earnings Date May 13 Volume 53,138 Change -1.43%
About Galectin Therapeutics Inc.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with nonalcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Galectin Therapeutics Inc. News
04/09/24 Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
03/29/24 Galectin Therapeutics Inc (GALT) Reports 2023 Financial Results and Business Developments
03/29/24 Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
03/12/24 Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development
02/21/24 Retail investors account for 55% of Galectin Therapeutics Inc.'s (NASDAQ:GALT) ownership, while insiders account for 21%
11/13/23 Galectin Therapeutics Inc (GALT) Reports Increased Net Loss in Q3 2023
11/13/23 UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update
11/13/23 Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update
11/03/23 Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD
10/23/23 Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023
10/12/23 Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors
10/03/23 Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis
09/26/23 Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023
09/14/23 Galectin Therapeutics Inc. (NASDAQ:GALT) surges 16%; individual investors who own 59% shares profited along with insiders
09/13/23 Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023
09/11/23 Galectin Therapeutics Inc. (GALT)'s Technical Outlook is Bright After Key Golden Cross
09/07/23 Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023
08/17/23 What Makes Galectin Therapeutics Inc. (GALT) a New Buy Stock
08/14/23 Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update
05/18/23 7 Short-Interest Stocks to Target for Explosive Gains
GALT Chatroom

User Image Bela9 Posted - 6 hours ago

$GALT I’m in since 09. Seen a lot.

User Image Okenrav Posted - 13 hours ago

$AKRO $ALT $GALT $MDGL $VKTX 🐂💩! All he did was to enable humanity to drink thrice as much before cirrhosis eventually reigns supreme.

User Image All_just_a_game Posted - 13 hours ago

$MDGL $ALT $VKTX $GALT $AKRO RIP to a man who helped many lives and advanced humanity….even after his death, with all his contributions to medicine, many will benefit.

User Image 2TrustHim Posted - 14 hours ago

$GALT Who’s Loading?

User Image Wardstock Posted - 17 hours ago

$GALT I've been here for 10 years and seen some crazy runs, but this is crazy..

User Image BIGT80 Posted - 18 hours ago

$GALT we be creeping!

User Image BIGT80 Posted - 19 hours ago

$GALT get excited folks!!

User Image BIGT80 Posted - 1 day ago

$GALT buy, hold and wait until at least $11 to sell any.

User Image qwertylicious2003 Posted - 1 day ago

$GALT

User Image BullsOnParade79 Posted - 1 day ago

$GALT this stock is mostly held by insiders and longs with no intention of selling shares until data or right before it. I imagine that it will be increasingly difficult to acquire large amounts of shares from now until December.

User Image BIGT80 Posted - 1 day ago

$GALT To my fellow longs! One way or another we will have our day!

User Image vettebk Posted - 1 day ago

$GALT I am happy with the NASH progress. But I believe the real power of belapectin will be to supercharge cancer therapies. That will be the gold ring and could be the real cause of GALT to be over $25 a share.

User Image vettebk Posted - 1 day ago

$GALT They dragged it down so someone could buy in mighty cheap. I didn't get the memo and bought more at 3.81 and 3.51. Will add more.

User Image BIGT80 Posted - 1 day ago

$GALT hold the line!

User Image Dingo2 Posted - 1 day ago

$GALT in for the long haul along with $ADMA and $ANVS and a few others that are somewhat behaving LOL

User Image mcube1820 Posted - 1 day ago

$GALT Have there been any indication posted anywhere of the likelihood of approval later this year? Just curious.

User Image BIGT80 Posted - 1 day ago

$GALT bounce!!!!

User Image Manny_Castro Posted - 2 days ago

$GALT Results eta Dec. 2024 https://classic.clinicaltrials.gov/ct2/show/NCT04365868

User Image Manny_Castro Posted - 2 days ago

$GALT Board of director member just purchased 10k worth of stocks

User Image Manny_Castro Posted - 2 days ago

$GALT

User Image Manny_Castro Posted - 2 days ago

$GALT https://galectintherapeutics.com/development-programs/

User Image insiderbuyingselling Posted - 2 days ago

$GALT new insider buying: 2500 shares. http://insiderbuyingselling.com/?t=GALT

User Image D_Coral Posted - 2 days ago

$GALT $XBI Large new research study - U Penn, Carnegie Mellon — “Lipid nanoparticles (LNPs) have emerged as the dominant platform for RNA delivery, based on their success in the COVID-19 vaccines and late-stage clinical studies in other indications. However, we and others have shown that LNPs induce severe inflammation, and massively aggravate pre-existing inflammation.” 🧬 “We find that inhibition of galectins abrogates LNP-associated inflammation, both in vitro and in vivo.” 🧬 “The inflammation can be controlled by inhibiting galectins (large hole detectors) or by using biodegradable lipids, which create smaller holes that are reparable by the ESCRT pathway. These strategies should lead to generally safer LNPs that can be used to treat inflammatory diseases.” Lipid Nanoparticle-Associated Inflammation is Triggered by Sensing of Endosomal Damage: Engineering Endosomal Escape without Side Effects https://www.biorxiv.org/content/10.1101/2024.04.16.589801v1

User Image smolcapcat Posted - 2 days ago

$GALT added some more, my average cost is sitting at 2.10

User Image D_Coral Posted - 2 days ago

$GALT Added more this morning in the artificial dip.

User Image BIGT80 Posted - 2 days ago

$GALT IMO I would wait to buy until the high $1's. My past experience tells me that's where we are headed again. Granted I'm hoping it's only back in the $1's for a short term. It's been in the $1's way more the past 5 years then in the $4's...so sad.

User Image oguzt Posted - 2 days ago

$GALT Never underestimate the psychological aspect of stock investing, especially when dealing with small or micro-cap stocks. Larger investors will always attempt to manipulate prices in order to induce stress and prompt you to sell your shares at a lower price. This essentially results in a wealth transfer where you will not benefit from significant upward price movements.

User Image Expharmaguy Posted - 2 days ago

$GALT We know the IA is in the Fall. We know that around end of August, the 357th patient will have completed the protocol. So beginning in Sept, the data will be analyzed, and organized to be submitted to the AASLD meeting in San Diego which starts Nov, 15th. So price decline now is no cause for alarm, since there are likely no catalysts coming until the Fall. For investors who have risk tolerance, and risk capacity, the drop represents a buying opportunity.

User Image oguzt Posted - 2 days ago

$GALT if you sell now, you are going to regret a lot later.

User Image BIGT80 Posted - 2 days ago

$GALT well this sucks…

Analyst Ratings
HC Wainwright & Co. Buy Apr 9, 24
HC Wainwright & Co. Buy Apr 1, 24
HC Wainwright & Co. Buy Aug 15, 23
HC Wainwright & Co. Buy May 17, 23
HC Wainwright & Co. Buy Mar 3, 23
HC Wainwright & Co. Buy May 17, 22
HC Wainwright & Co. Buy Apr 16, 21
HC Wainwright & Co. Buy Aug 13, 20
B. Riley Securities Buy Apr 3, 20
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
ELDRED KARY Director Director Jan 16 Buy 1.7858 500 893 49,313 01/16/24
Uihlein Richard E Director Director Sep 26 Option 3.85 2,236,204 8,609,385 10,235,495 09/27/23
ELDRED KARY Director Director Jul 19 Buy 1.786 1,598 2,854 48,813 07/20/23
ELDRED KARY Director Director Feb 21 Buy 1.5911 1,000 1,591 47,215 02/21/23
LEWIS JOEL President and CEO President and CEO Feb 16 Buy 1.52 1,000 1,520 1,000 02/21/23
ELDRED KARY Director Director Jan 25 Buy 1.11 1,300 1,443 46,215 01/26/23
FREEMAN KEVIN D Director Director Oct 28 Buy 1.41 10,000 14,100 75,000 10/31/22
10X Fund, L.P. 10% Owner 10% Owner Jul 27 Sell 2.087 10,000 20,870 6,168,940 08/15/22
10X Fund, L.P. 10% Owner 10% Owner Jul 22 Sell 2.087 10,000 20,870 6,168,940 08/09/22
Zordani Richard A. Jr. Director Director Jul 28 Buy 2.5 5,000 12,500 29,583 07/29/22
FREEMAN KEVIN D Director Director May 19 Buy 1.3299 5,000 6,650 65,000 05/20/22
10X Fund, L.P. 10% Owner 10% Owner Feb 02 Sell 2.10 10,000 21,000 6,178,940 02/04/22
Schwartz Elissa J. Director Director Jan 21 Buy 2 1,000 2,000 1,000 01/24/22
FREEMAN KEVIN D Director Director Jan 19 Buy 1.9612 5,000 9,806 50,000 01/19/22
Zordani Richard A. Jr. Director Director Jan 14 Buy 2.02 5,000 10,100 19,583 01/18/22
10X Fund, L.P. 10% Owner 10% Owner Jan 11 Sell 2.10 10,000 21,000 6,188,940 01/13/22